Adipokines and inflammation markers and risk of differentiated thyroid carcinoma: The EPIC study
暂无分享,去创建一个
A. Fournier | E. Riboli | P. Vineis | C. la Vecchia | S. Franceschi | A. Tjønneland | K. Overvad | E. Weiderpass | P. Peeters | A. Trichopoulou | K. Khaw | I. Romieu | R. Kaaks | D. Palli | C. Biessy | S. Panico | R. Tumino | A. Scalbert | F. Bonnet | H. Bueno-de-Mesquita | A. Olsen | M. Boutron‐Ruault | D. Aune | R. Fortner | K. Tsilidis | M. Dorronsoro | R. Travis | C. Agnoli | L. Nilsson | E. Ardanaz | L. Dossus | G. Skeie | Julie A. Schmidt | M. Chirlaque | María-José Sánchez | S. Rinaldi | R. Zamora-Ros | K. Aleksandrova | J. Ramón Quirós | E. Peppa | M. Sandström | Anne-Sophie Navionis | H. Bueno‐de‐Mesquita | M. Sánchez | Eleni Peppa | S. Rinaldi | E. Riboli
[1] G. Kismali,et al. Evaluation of Proinflammatory Cytokine and Neopterin Levels in Women with Papillary Thyroid Carcinoma , 2016, The International journal of biological markers.
[2] K. Straif,et al. Body Fatness and Cancer--Viewpoint of the IARC Working Group. , 2016, The New England journal of medicine.
[3] Martyn Plummer,et al. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. , 2016, The New England journal of medicine.
[4] P. Scherer,et al. Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. , 2016, Cell metabolism.
[5] Li-Ling Wu,et al. Circulating adiponectin levels in various malignancies: an updated meta-analysis of 107 studies , 2016, Oncotarget.
[6] T. Trivedi,et al. Significance of Interleukin-6 in Papillary Thyroid Carcinoma , 2016, Journal of thyroid research.
[7] Elizabeth E Ward,et al. Anthropometric Factors and Thyroid Cancer Risk by Histological Subtype: Pooled Analysis of 22 Prospective Studies. , 2016, Thyroid : official journal of the American Thyroid Association.
[8] G. H. Patel,et al. Significance of TNF-α and the Adhesion Molecules: L-Selectin and VCAM-1 in Papillary Thyroid Carcinoma , 2016, Journal of thyroid research.
[9] E. Mingomataj,et al. Regulator Versus Effector Paradigm: Interleukin-10 as Indicator of the Switching Response , 2016, Clinical Reviews in Allergy & Immunology.
[10] M. Leitzmann,et al. Adiposity and risk of thyroid cancer: a systematic review and meta‐analysis , 2015, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[11] N. Serdarevic,et al. IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis , 2015, Scandinavian journal of clinical and laboratory investigation.
[12] Z. Jovanovic,et al. Cytokine production in patients with papillary thyroid cancer and associated autoimmune Hashimoto thyroiditis , 2015, Cancer Immunology, Immunotherapy.
[13] I. Gram,et al. Inflammatory Markers and Risk of Epithelial Ovarian Cancer by Tumor Subtypes: The EPIC Cohort , 2015, Cancer Epidemiology, Biomarkers & Prevention.
[14] J. Araújo,et al. The Role of the Mediators of Inflammation in Cancer Development , 2015, Pathology & Oncology Research.
[15] C. Mathers,et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012 , 2015, International journal of cancer.
[16] S. Gandini,et al. Circulating adiponectin and breast cancer risk: a systematic review and meta-analysis. , 2014, International journal of epidemiology.
[17] U. Nöthlings,et al. Inflammatory and metabolic biomarkers and risk of liver and biliary tract cancer , 2014, Hepatology.
[18] M. Plummer,et al. Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. , 2014, Journal of the National Cancer Institute.
[19] T. Abdel-Aziz,et al. Study of Serum Leptin in Well-differentiated Thyroid Carcinoma: Correlation with Patient and Tumor Characteristics , 2014, World Journal of Surgery.
[20] T. Sergentanis,et al. Interleukins as markers of inflammation in malignant and benign thyroid disease , 2014, Inflammation Research.
[21] F. Clavel-Chapelon,et al. C-reactive protein and postmenopausal breast cancer risk: results from the E3N cohort study , 2014, Cancer Causes & Control.
[22] Y. Altuntas,et al. Interleukin-10-1082 gene polymorphism is associated with papillary thyroid cancer , 2014, Molecular Biology Reports.
[23] Zhibin Chen,et al. Autoimmunity as a Double Agent in Tumor Killing and Cancer Promotion , 2014, Front. Immunol..
[24] Vandana Saini,et al. Role of leptin and adiponectin in insulin resistance. , 2013, Clinica chimica acta; international journal of clinical chemistry.
[25] Chien-Liang Liu,et al. Expression and Biologic Significance of Adiponectin Receptors in Papillary Thyroid Carcinoma , 2012, Cell Biochemistry and Biophysics.
[26] C. Mantzoros,et al. The role of adiponectin in cancer: a review of current evidence. , 2012, Endocrine reviews.
[27] R. Melillo,et al. Inflammation in thyroid oncogenesis. , 2012, American journal of cancer research.
[28] J. Chang-Claude,et al. Tumor necrosis factor (TNF)‐α, soluble TNF receptors and endometrial cancer risk: The EPIC study , 2011, International journal of cancer.
[29] C. Mantzoros,et al. Circulating adiponectin is inversely associated with risk of thyroid cancer: in vivo and in vitro studies. , 2011, The Journal of clinical endocrinology and metabolism.
[30] L. L. Cunha,et al. Interleukin-10 but not interleukin-18 may be associated with the immune response against well-differentiated thyroid cancer , 2011, Clinics.
[31] D. Hanahan,et al. Hallmarks of Cancer: The Next Generation , 2011, Cell.
[32] Hong-Kyu Kim,et al. High-Sensitivity C-Reactive Protein and Cancer , 2011, Journal of epidemiology.
[33] F. Clavel-Chapelon,et al. Obesity, inflammatory markers, and endometrial cancer risk: a prospective case–control study , 2010, Endocrine-related cancer.
[34] G. Hallmans,et al. Temporal reliability of cytokines and growth factors in EDTA plasma , 2010, BMC Research Notes.
[35] E. Ron,et al. Exposing the thyroid to radiation: a review of its current extent, risks, and implications. , 2010, Endocrine reviews.
[36] F. Clavel-Chapelon,et al. Circulating C-reactive protein concentrations and risks of colon and rectal cancer: a nested case-control study within the European Prospective Investigation into Cancer and Nutrition. , 2010, American journal of epidemiology.
[37] R. Orlando,et al. Cytokines, thyroid diseases and thyroid cancer. , 2010, Cytokine.
[38] M. Castellone,et al. Thyroid cancer and inflammation , 2010, Molecular and Cellular Endocrinology.
[39] R. Ferris,et al. Multiplex analysis of cytokines as biomarkers that differentiate benign and malignant thyroid diseases , 2008, Proteomics. Clinical applications.
[40] Nahum Sonenberg,et al. The Effects of Adiponectin and Metformin on Prostate and Colon Neoplasia Involve Activation of AMP-Activated Protein Kinase , 2008, Cancer Prevention Research.
[41] M. Karadeniz,et al. Interleukin-10 gene polymorphism in patients with papillary thyroid cancer in Turkish population , 2008, Journal of endocrinological investigation.
[42] C. Dive,et al. Obesity and cancer: Pathophysiological and biological mechanisms , 2008, Archives of physiology and biochemistry.
[43] W. Willett,et al. Plasma adiponectin concentrations and risk of incident breast cancer. , 2006, The Journal of clinical endocrinology and metabolism.
[44] C. Friedenreich,et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. , 2007, The Journal of clinical endocrinology and metabolism.
[45] Herbert Tilg,et al. Adipocytokines: mediators linking adipose tissue, inflammation and immunity , 2006, Nature Reviews Immunology.
[46] L. Ricci-Vitiani,et al. Autocrine production of interleukin-4 and interleukin-10 is required for survival and growth of thyroid cancer cells. , 2006, Cancer research.
[47] S. Kihara,et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[48] C. la Vecchia,et al. A pooled analysis of case–control studies of thyroid cancer. IV. Benign thyroid diseases , 1999, Cancer Causes & Control.
[49] K. Wellen,et al. Obesity-induced inflammatory changes in adipose tissue. , 2003, The Journal of clinical investigation.
[50] R. Henry,et al. Adiponectin: more than just another fat cell hormone? , 2003, Diabetes care.
[51] S. Katayose,et al. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. , 2003, European journal of endocrinology.
[52] N E Day,et al. European Prospective Investigation into Cancer and Nutrition (EPIC): study populations and data collection , 2002, Public Health Nutrition.
[53] S. Uchida,et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.
[54] G M Besser,et al. Serum cytokines in thyrotoxicosis. , 1999, The Journal of clinical endocrinology and metabolism.